Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

ACell MatriStem Pelvic Floor Matrix Versus Native Tissue Repair, Comparative Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02021279
Recruitment Status : Active, not recruiting
First Posted : December 27, 2013
Last Update Posted : March 19, 2020
Sponsor:
Information provided by (Responsible Party):
ACell Inc.

Brief Summary:
The primary objective of this study is to assess the safety and effectiveness of MatriStem Pelvic Floor Matrix as compared to native tissue repair for the treatment of pelvic organ prolapse. Patients are evaluated throughout a 3 year follow-up period.

Condition or disease Intervention/treatment Phase
Pelvic Organ Prolapse Device: MatriStem Pelvic Floor Matrix Procedure: native tissue repair Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 162 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of the Use of Transvaginal Resorbable Biologic Mesh as Compared to Traditional Non-Mesh Surgical Repair for Treating Pelvic Floor Disorders
Study Start Date : June 2014
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : December 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: MatriStem Pelvic Floor Matrix
surgical mesh device
Device: MatriStem Pelvic Floor Matrix
Active Comparator: Native Tissue Repair
suture repair
Procedure: native tissue repair
Other Name: suture repair




Primary Outcome Measures :
  1. The safety and effectiveness of surgical success/failure. [ Time Frame: 3 years ]
    The composite outcome of surgical success evaluates anatomic outcome, patient reported outcome, and no retreatment pelvic organ prolapse.


Secondary Outcome Measures :
  1. The surgical success/failure based on an alternate definition of success. [ Time Frame: 3 years ]
    A composite outcome of surgical success based on an alternate definition of anatomic success, patient reported outcome, and no retreatment for pelvic organ prolapse.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Subject's leading edge of POP is at or beyond the hymen. At or beyond the hymen is defined as POP-Q scores of Ba ≥ 0 or Bp ≥ 0 or C ≥ 0 (for prolapse of the apical compartment alone) or C ≥ -½ total vaginal length (for a multi-compartment prolapse that includes the apical compartment).
  • Subject is seeking surgical intervention for symptomatic POP, which is defined as experiencing symptoms of vaginal bulging or pelvic heaviness. Vaginal bulge or pelvic heaviness will be considered present if a subject responds "yes" (≥1) to PFDI-20, question 3.
  • Subject or subject's legally authorized representative is willing to provide written informed consent.
  • Subject is willing and able to comply with the follow-up regimen.

Exclusion Criteria:

  • Subject has a known hypersensitivity to porcine-based materials (relevant to subjects in MatriStem Pelvic Floor Matrix Group only).
  • Subject is pregnant or plans to become pregnant during the study.
  • Subject has an active or chronic systemic infection including any gynecologic infection, urinary tract infection (UTI), or tissue necrosis.
  • Subject has a known neurologic or medical condition affecting bladder function (e.g. multiple sclerosis, spinal cord injury, or stroke with residual neurologic deficit).
  • Subject has chronic systemic pain syndrome (e.g. fibromyalgia, painful bladder syndrome).
  • Subject has a systemic connective tissue disease (e.g., scleroderma, systemic lupus erythematous (SLE), Marfans syndrome, Ehlers Danhlos, collagenosis, polymyositis or polymyalgia rheumatica).
  • Subject has uncontrolled diabetes mellitus (DM).
  • Subject has a history of pelvic organ cancer (e.g. uterine, ovarian, bladder, or cervical).
  • Subject has had prior or is currently undergoing radiation, laser therapy, or chemotherapy in the pelvic area.
  • Subject has taken systemic steroids (within the last month), immunosuppressive or immunomodulatory treatment (within the last 3 months).
  • Subject is seeking obliterative vaginal surgery as treatment for POP (colpoclesis).
  • Subject is not able to conform to the modified dorsal lithotomy position.
  • Subject is currently participating in or plans to participate in another device or drug study during this study.
  • Subject is to planning to undergo concurrent surgical treatment of prolapse using mesh other than the MatriStem Pelvic Floor Matrix.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02021279


Locations
Layout table for location information
United States, California
Stanford School of Medicine
Stanford, California, United States, 94305
United States, Florida
Cleveland Clinic FLorida
Weston, Florida, United States, 33331
United States, Michigan
Female Pelvic Medicine & Urogynecology
Grand Rapids, Michigan, United States, 49503
United States, New Jersey
Premier Urology Group
Edison, New Jersey, United States, 08837
Atlantic Health System
Morristown, New Jersey, United States, 07960
Princeton Urogynecology
Princeton, New Jersey, United States, 08540
Garden State Urology
Whippany, New Jersey, United States, 07981
United States, New York
Premier Medical Group of the Hudson Valley
Poughkeepsie, New York, United States, 12601
United States, Ohio
The Christ Hospital
Cincinnati, Ohio, United States, 45219
Cleveland Clinic Foundation
Cleveland, Ohio, United States, 44195
United States, Oklahoma
University of Oklahoma Health Sciences Center
Oklahoma City, Oklahoma, United States, 73104
United States, Pennsylvania
The Institute for Female Pelvic Medicine and Reconstructive Surgery
Allentown, Pennsylvania, United States, 18103
United States, Tennessee
Center for Pelvic Health
Franklin, Tennessee, United States, 37067
Sponsors and Collaborators
ACell Inc.
Layout table for additonal information
Responsible Party: ACell Inc.
ClinicalTrials.gov Identifier: NCT02021279    
Other Study ID Numbers: ACL2012-001
First Posted: December 27, 2013    Key Record Dates
Last Update Posted: March 19, 2020
Last Verified: March 2020
Keywords provided by ACell Inc.:
pelvic organ prolapse
MatriStem
pelvic floor matrix
ACell
native tissue repair
Additional relevant MeSH terms:
Layout table for MeSH terms
Prolapse
Pelvic Organ Prolapse
Pathological Conditions, Anatomical